RIVASTIGMINE Tartrate Capsules — Class III drug recall D-0649-2017
Terminated recall by Dr. Reddy's Laboratories, Inc., reported 2017-04-12, distributed nationwide. Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 m
| Recall number | D-0649-2017 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Dr. Reddy's Laboratories, Inc., Princeton, NJ, United States |
| Recall initiated | 2017-03-06 |
| Classified | 2017-04-06 |
| Reported by FDA | 2017-04-12 |
| Terminated | 2017-12-21 |
| Distributed | Nationwide (US) |
| Quantity | 1,728 bottles |
| NDC | 55111-0352, 55111-0352-01, 55111-0352-05, 55111-0352-30, 55111-0352-60, 55111-0353, 55111-0353-01, 55111-0353-05, 55111-0353-30, 55111-0353-60, 55111-0354, 55111-0354-01, 55111-0354-05, 55111-0354-30, 55111-0354-60, 55111-0355, 55111-0355-01, 55111-0355-05, 55111-0355-30, 55111-0355-60 |
| Lot numbers | 10/18, C607323 |
Product
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60
Reason for recall
Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0649-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.